Presentation is loading. Please wait.

Presentation is loading. Please wait.

Illustration of σ down-regulation in bladder carcinomas.

Published byAngelika Beutel Modified over 5 years ago

Similar presentations

Presentation on theme: "Illustration of σ down-regulation in bladder carcinomas."— Presentation transcript:

1 Illustration of 14-3-3σ down-regulation in bladder carcinomas.
Illustration of σ down-regulation in bladder carcinomas. Magnified sections of representative 2D PAGE gels run with lysates from normal urothelium (cyst 473, cyst 975) and TCCs of various grades and stages (916-1 pTa G1; pTa G2; 702 pT2-4 G3; 697 pT1 G3; pT1 G3; 566 pT2-4 G4). Gels were visualized by autoradiography. Arrowheads indicate the position of σ in the various gels. Expression levels of σ are divided into high (H), medium (M), or low (L). José M. A. Moreira et al. Mol Cell Proteomics 2004;3: © 2004 The American Society for Biochemistry and Molecular Biology

Download ppt "Illustration of σ down-regulation in bladder carcinomas."

Similar presentations

Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.

Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.
Sequence alignment of C-terminal phosphorylated plant aquaporins

Sequence alignment of C-terminal phosphorylated plant aquaporins
Phosphorylation and sequence disorder in microtubule-associated protein Tau.A, schematic illustration of the domain profile of Tau with all known phosphorylation.

Phosphorylation and sequence disorder in microtubule-associated protein Tau.A, schematic illustration of the domain profile of Tau with all known phosphorylation.
Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,

Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,
Fast protein LC IMAC purification of cytosolic phosphoproteins

Fast protein LC IMAC purification of cytosolic phosphoproteins
A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.

A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.
Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.

Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.
Julio E Celis, Pavel Gromov  Cancer Cell 

Julio E Celis, Pavel Gromov  Cancer Cell 
Illustration of matched (FL-IFN-γR2/GFP and IFN-γR1/EBFP) and mismatched (IFN-γR1/EBFP and FL-IL-10R2/GFP) pairs of receptors. Illustration of matched.

Illustration of matched (FL-IFN-γR2/GFP and IFN-γR1/EBFP) and mismatched (IFN-γR1/EBFP and FL-IL-10R2/GFP) pairs of receptors. Illustration of matched.
Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,

Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,
Examples of cancer tissue profiles.

Examples of cancer tissue profiles.
Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.

Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.
Visual validation of the computational outputs.

Visual validation of the computational outputs.
Novel p53 target genes identified by RNA-Seq, pSILAC and ChIP-Seq.

Novel p53 target genes identified by RNA-Seq, pSILAC and ChIP-Seq.
Assay of NOS activity. Assay of NOS activity. Box show total NOS activity, the calcium-dependent activity of the constitutive isoforms of NOS (eNOS and.

Assay of NOS activity. Assay of NOS activity. Box show total NOS activity, the calcium-dependent activity of the constitutive isoforms of NOS (eNOS and.
Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.

Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.
Relative abundance of proteins identified in MALDI IMS

Relative abundance of proteins identified in MALDI IMS
Experimental setup.A, topology models of the overexpressed membrane protein GFP fusions. Experimental setup.A, topology models of the overexpressed membrane.

Experimental setup.A, topology models of the overexpressed membrane protein GFP fusions. Experimental setup.A, topology models of the overexpressed membrane.
Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.

Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.
Success rates in validation of antibodies from external providers

Success rates in validation of antibodies from external providers

Similar presentations

Ads by Google